Flexion Therapeutics' FX006, a sustained-release formulation of the steroid triamcinolone, has been able to deliver drug to the knee joint in people with osteoarthritis for 6 weeks or more.
Instead of taking assets to proof-of-concept in a fast march through the clinic and then striking deals for their programs, as originally planned, Flexion's top execs have seized on the success of their clinical-stage osteoarthritis drugs and plan to stay focused on their pipeline--pursuing late-stage work, perhaps all the way through Phase III.
Array BioPharma touted its latest mid-stage study of a key pain drug as an unqualified success, beating a placebo and hitting its primary endpoint when tested in patients suffering from osteoarthritis. But when investors dug down into the release and found that its experimental med did no better than a standard treatment, its shares slid more than 11%.
Total hip and total knee replacement surgeries may be a boon to patients with osteoarthritis, restoring mobility and greatly reducing pain. But within the first two weeks after the surgical procedures are performed, these patients face a greater risk of heart attack, according to a new study in the Netherlands evaluating data from thousands of Danish patients.
This morning, Flexion announced that they hit the proof-of-concept stage as planned. Top-line results demonstrated that the intra-articularly delivered FX005 hit its primary endpoint on pain relief and function among osteoarthritis patients.
Levels of proteins in a single drop of the fluid surrounding the damaged joint can be used to detect whether the patient is developing arthritis, as well as to predict the potential severity of the disease.
Novartis researchers discovered that a compound called kartogenin promoted the repair of damaged cartilage in arthritic mice.
Clearing a major roadblock that's keeping Big Pharma from a megablockbuster drug market, a group of FDA experts voted unanimously to allow Pfizer and several other developers to resume testing a...
Researchers have isolated an osteoarthritis biomarker, D-COMP (deaminated cartilage oligomeric matrix protein) that has seemingly conflicting effects: in the circulation, it marks degeneration in the
In research presented at the Orthopaedic Research Society 2012 annual meeting, two biomarkers have come to light that might help in the development of disease-modifying treatments for osteoarthritis,